Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 233-020-5 | CAS number: 10022-31-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Acute Toxicity: dermal
Administrative data
- Endpoint:
- acute toxicity: dermal
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Justification for type of information:
- Test material for this study report is barium chloride - a highly soluble barium salt which dissociates to the Ba2+ ion and Cl- ions in solutions in a similar way to barium nitrate dissociating to Ba2+ and NO3- ions. It is generally accepted that it is the Ba2+ ions that control the toxicology of barium compounds and not the anions, and it is deemed reasonable to consider barium chloride as a good surrogate to the nitrate for toxicology end points.
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 008
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 402 (Acute Dermal Toxicity)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- fixed dose procedure
- Limit test:
- yes
Test material
- Reference substance name:
- Barium chloride
- EC Number:
- 233-788-1
- EC Name:
- Barium chloride
- Cas Number:
- 10361-37-2
- Molecular formula:
- BaCl2
- IUPAC Name:
- barium dichloride
Constituent 1
- Specific details on test material used for the study:
- Purity : 99.999%
Test animals
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Age: male (8-week), female (9-week)
Weighing: male (265.4-290.7 g), female (220.0-263.5 g)
Environmental conditions
Temperature: 20.7-22.9 °C
Relative humidity : 42.5-49.2 %
Air ventilation frequency: 10-15 times/hr
Light intensity: 150-300 Lux
Light/dark cycle: 12-hour/day
Administration / exposure
- Type of coverage:
- semiocclusive
- Vehicle:
- unchanged (no vehicle)
- Details on dermal exposure:
- Individual dose was calculated based on the animal’s body weight taken just before dosing. A dose for each animal was weighed using an electronic balance (CP323S, Sartorius, Germany). The area of dorsal skin (approximately 5 cm x 6 cm) on each animal’s back was clipped free of hair with an electric clipper (5000ADII, NATUME, Japan, size: 0.05 m). The area of 4 cm x 5 cm on the back was established as the application site. After the application of the test substance to gauze, the gauze was moistened with the water of injection (Lot No. : GBA8003, Choongwae Pharma Corp., stored at normal temperature) sufficiently, and the application site was covered with the gauze and plastic film. Each animal’s back was over-wrapped with a Soft Cloth Tape with Liner (5 cm width, 3M Co., Ltd., Korea). At the end of a 24-hour exposure period, the gauze, plastic film, and Soft Cloth Tape with Liner were removed, and any residual test substance was removed using absorbent cotton moistened with tepid water. The application site of the control animals was dressed without topical application of the test substance in the same manner as the treatment group.
- Duration of exposure:
- 24 hours
- Doses:
- Control : 0 mg/kg
Test concentration : 2000 mg/kg - No. of animals per sex per dose:
- 5
- Control animals:
- yes
- Details on study design:
- On the day of administration, clinical signs (including general appearance, motility, function of the autonomic nervous system, and discharge) and mortality were observed continuously for up to 30 minutes after dosing, and then observed at 1, 2, 4, and 6 hours after dosing. During a 14-day observation period, clinical signs were observed once daily.
[Body weight]
Body weights were measured prior to dosing (Day 0), on Day 1, 3, 7, and the day of necropsy (Day 14).
[Necropsy]
After the end of the observation period, all of the animals were exsanguinated by transecting the abdominal aorta under CO2 gas anesthesia and observed macroscopically about full external surface and organs of thoracic and abdominal cavities.
[Histopathological findings]
Since no gross findings were observed at necropsy, histopathological examinations were not performed - Statistics:
- Statistical analysis was performed using the statistical Program (SAS 9.1.3, SAS Institute Inc., U.S.A.). Folded-F test was done to test for variance homogeneity at the 5.0% one-tailed probability level. Student t-test was employed on homogeneous data for the control group versus treatment group comparison at the 5.0 and 1.0% two-tailed probability level.
Results and discussion
- Preliminary study:
- The dose levels for the study were determined referring to the result of the preliminary study (Study No.; B08069p). There were no toxic signs on mortality, clinical signs, body weight change and gross findings at the 2000 mg/kg levels of the preliminary study. Therefore, the limit dose level of 2000 mg/kg was selected
Effect levels
- Key result
- Sex:
- male/female
- Dose descriptor:
- LD50
- Effect level:
- > 2 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- During the observation period, there were no deaths of all males and females in the control and treatment groups
- Clinical signs:
- other: A hematuria was observed in one female rat treated with 2000 mg/kg from Day 2 to Day 11 after administration. From Day 12 after administration, this abnormality was returned to normal appearance. This abnormality was not considered to the toxic effect fro
- Gross pathology:
- No treatment-related gross findings were observed in all animals
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Based on these results, no toxic effect was observed and the LD50 value of barium chloride in acute dermal toxicity study was considered to be more than 2000 mg/kg bw on male and female rats.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.